Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Leukemia. 2014 Nov 26;29(4):988–991. doi: 10.1038/leu.2014.327

Figure 1. Outcome according to pre-HCT and post-HCT residual disease status by either immunophenotypic assay of LSC populations (MFC-LSC) or by standard flow cytometric detection (MFC-MRD).

Figure 1

Figure 1

Figure 1

A: Relapse free survival (RFS) by MFC-LSC status pre HCT. B: RFS by MFC-MRD status pre HCT

C: Relapse free survival (RFS) by MFC-LSC status at any time-point post HCT. D: RFS by MFC-MRD status at any time-point post HCT.

E: Overall survival (OS) by MFC-LSC status at any time-point post-HCT. F: OS by MFC-MRD status at any time-point post HCT